Merab Joseph, MD
Endocrinology · Fair Lawn, NJNPI 1053421032
Payments from drug & device makers
Across 570 payments — averaging $174.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$77K
- Lilly USA, LLC$16K
- Medtronic$2K
- Novo Nordisk$807
- Amgen$758
- Sanofi-aventis U.S. LLC$702
- plus $2K from 31 others
What the payments were for
- Consulting fees$2,9253%
- Speaking & faculty fees$84,57585%
- Travel & lodging$1,6592%
- Food & beverage$10,31110%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 122 | $77,134 |
| Lilly USA, LLC | 127 | $16,154 |
| Medtronic(2 entities) | 16 | $1,621 |
| Novo Nordisk | 58 | $807 |
| Amgen | 42 | $758 |
| Sanofi-aventis U.S. LLC | 51 | $702 |
| AstraZeneca(2 entities) | 36 | $512 |
| AbbVie | 17 | $252 |
| Merck | 14 | $190 |
| Xeris Pharmaceuticals, Inc. | 12 | $186 |
| Amneal Pharmaceuticals LLC | 8 | $121 |
| Radius Health, Inc. | 7 | $100 |
| Insulet Corporation | 6 | $97 |
| Abbott | 5 | $87 |
| Bayer | 5 | $86 |
| Pfizer | 4 | $54 |
| Dexcom, Inc. | 3 | $51 |
| Corcept Therapeutics | 3 | $48 |
| Azurity Pharmaceuticals, Inc. | 3 | $46 |
| Johnson & Johnson | 3 | $42 |
| Novartis | 2 | $37 |
| Cequr Corporation | 2 | $37 |
| Recordati_rare_diseases_inc. | 2 | $34 |
| Ascendis Pharma Endocrinology Inc | 2 | $33 |
| Madrigal Pharmaceuticals | 2 | $31 |
| Amryt Pharma Holdings Ltd | 2 | $31 |
| Tandem Diabetes Care, Inc. | 2 | $30 |
| Mannkind Corporation | 2 | $29 |
| Vistapharm, Inc. | 2 | $29 |
| Shire North American Group Inc | 2 | $27 |
| IBSA Pharma Inc. | 2 | $26 |
| Zealand Pharma US, Inc. | 1 | $17 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Senseonics, Incorporated | 1 | $15 |
| Tolmar, Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| BD | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$91,226
- Minimed 670G System$1,373
- EVENITY$125
How this compares
Too few endocrinology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 670 | $677,583 |
| JardianceEmpagliflozin | 589 | $502,645 |
| MounjaroTirzepatide | 350 | $379,007 |
| JanuviaSitagliptin Phosphate | 205 | $150,404 |
| JanumetSitagliptin Phos/Metformin Hcl | 177 | $143,879 |
| TrulicityDulaglutide | 106 | $130,505 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 215 | $119,104 |
| TradjentaLinagliptin | 178 | $117,182 |
| FarxigaDapagliflozin Propanediol | 142 | $103,365 |
| Tresiba Flextouch U-200Insulin Degludec | 138 | $84,992 |
| Cinacalcet Hcl | 152 | $74,902 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 116 | $72,051 |
| Humalog Kwikpen U-100Insulin Lispro | 368 | $70,598 |
| ProliaDenosumab | 39 | $66,028 |
| GlyxambiEmpagliflozin/Linagliptin | 68 | $64,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy Xr, Synjardy | $77,134 | $823,2521,010 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp | $807 | $712,114716 claims |
| Lilly USA, LLCMounjaro, Trulicity | $16,154 | $509,512456 claims |
| MerckJanuvia, Janumet, Janumet Xr | $190 | $413,387597 claims |
| AstraZenecaFarxiga | $512 | $103,365142 claims |
| AmgenProlia | $758 | $66,02839 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $702 | $38,96744 claims |
| AbbVieSynthroid | $252 | $14,639211 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $121 | $9,9521,215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Fair Lawn
- Oscar OrtizToms River$176K
- Caryn BorgerFlorham Park$68K
- Rama ReddyBelleville$8K
- Brian FertigPiscataway$4K
- Samar BurshehVentnor City$4K
- Monika AkulaNeptune$4K
- Saleh KhaddashClifton$2K
- Muqdad HasanGlen Ridge$900
- Andrew ParzialeMorristown$0
- Alexa YuenMorristown$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.